This study aims to evaluate the effects of nutrition education with or without rice bran supplementation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants were recruited from the Division of Gastroenterology and Hepatology at Changhua Christian Hospital and assigned to either a nutrition education (NE) group or a nutrition education plus rice bran (NERB) group. The intervention was conducted for a specified study period, during which participants received dietary guidance and follow-up assessments. The primary objective of this study is to determine whether rice bran supplementation in addition to nutrition education provides greater benefits on body weight, body mass index, dietary intake, and metabolic parameters compared with nutrition education alone. Secondary outcomes include changes in liver-related biochemical markers, glycemic indicators, lipid profiles, and other anthropometric measurements. This study may provide evidence on the potential role of rice bran as a functional dietary supplement for improving metabolic health in patients with MASLD and may support the development of practical nutritional strategies for disease management.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
58
Participants received structured nutrition education during the study period.
Participants received structured nutrition education together with rice bran supplementation during the intervention period.
Shih Chien University
Taipei, Taiwan
Change in body weight
Body weight was measured to evaluate the effect of nutrition education with or without rice bran supplementation.
Time frame: From enrollment to the end of treatment at 3 months
Change in body mass index
Body mass index was measured to evaluate the effect of nutrition education with or without rice bran supplementation.
Time frame: From enrollment to the end of treatment at 3 months
Change in waist circumference
Waist circumference was measured to assess changes in central adiposity following the intervention.
Time frame: From enrollment to the end of treatment at 3 months
Change in body fat percentage
Body fat percentage was measured to assess changes in body composition following the intervention.
Time frame: From enrollment to the end of treatment at 3 months
Change in visceral fat area
visceral fat area was measured to assess changes in body composition following the intervention.
Time frame: From enrollment to the end of treatment at 3 months
Change in energy intake
Energy intake was assessed to evaluate changes in dietary intake following the intervention.
Time frame: From enrollment to the end of treatment at 3 months
Change in dietary fiber intake
Dietary fiber intake was assessed to evaluate changes in dietary quality following the intervention.
Time frame: From enrollment to the end of treatment at 3 months
Change in fasting glucose
Fasting glucose was measured to assess the effect of the intervention on glycemic status.
Time frame: From enrollment to the end of treatment at 3 months
Change in HbA1c
HbA1c was measured to assess the effect of the intervention on glycemic status.
Time frame: From enrollment to the end of treatment at 3 months
Change in fasting insulin
Fasting insulin was measured to assess the effect of the intervention on insulin status.
Time frame: From enrollment to the end of treatment at 3 months
Change in triglycerides
Triglyceride levels were measured to assess the effect of the intervention on lipid metabolism.
Time frame: From enrollment to the end of treatment at 3 months
Change in HDL-cholesterol
HDL-cholesterol was measured to assess the effect of the intervention on lipid profile.
Time frame: From enrollment to the end of treatment at 3 months
Change in LDL-cholesterol
LDL-cholesterol was measured to assess the effect of the intervention on lipid profile.
Time frame: From enrollment to the end of treatment at 3 months
Change in alanine aminotransferase
Alanine aminotransferase was measured to assess the effect of the intervention on liver function.
Time frame: From enrollment to the end of treatment at 3 months
Change in aspartate aminotransferase
Aspartate aminotransferase was measured to assess the effect of the intervention on liver function.
Time frame: From enrollment to the end of treatment at 3 months
Change in FibroScan liver stiffness measurement (E, kPa)
FibroScan liver stiffness measurement was assessed to evaluate changes in liver stiffness following the intervention.
Time frame: From enrollment to the end of treatment at 3 months
Change in FibroScan controlled attenuation parameter (CAP, dB/m)
FibroScan controlled attenuation parameter was assessed to evaluate changes in hepatic steatosis following the intervention.
Time frame: From enrollment to the end of treatment at 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.